We published in the December issue of Nature Biotechnology a news analysis detailing some of the funding models being used by today’s life science investors. Some are looking to expand syndicates, ensuring that funding is there for follow-on rounds. One is sometimes providing huge A rounds by itself. And though many favor an “asset-based” approach, the R&D platform engine is not as dead as might be thought.
We’ve removed the article from behind our pay firewall, and you can read it here for the next month or so. It should be informative to the Trade Secrets audience.